Journal
DRUG DISCOVERY TODAY
Volume 17, Issue 5-6, Pages 242-252Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2011.12.021
Keywords
-
Categories
Funding
- Cancer Research UK [C309/A8274]
- UK Medical Research Council
- National Health Service at the Institute of Cancer Research
- Royal Marsden Hospital
- Cancer Research UK [11566] Funding Source: researchfish
Ask authors/readers for more resources
The early clinical hypothesis for inhibiting HSP90 in cancers was based on the dependence of certain key client proteins in malignant cells - including a host of well-characterized oncoproteins - on the activity of HSP90 for their function and stability. The additional concept has been established that cancer cells have heightened dependence on the efficient maintenance of intracellular proteomic homeostasis, central components of which are HSP90 and other heat shock proteins. We evaluate the evidence that inhibiting HSP90 in cancer exploits both of these biological vulnerabilities very effectively, we review the current status of the discovery and development of HSP90 inhibitors and we identify routes to improve their clinical efficacy, based on emerging knowledge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available